Brawn Biotech posts FY26 profit, but Q4 was weak
A full-year net profit of ₹94.06 lakhs masks a fourth quarter where revenue fell over 50% sequentially.
— 1 earlier story on Brawn Biotech Ltd. →What's new
- Brawn Biotech swung to a full-year net profit of ₹94.06 lakhs (EPS ₹3.26) from a net loss of ₹179.81 lakhs in FY25.
- Q4 FY26 revenue dropped over 50% sequentially to ₹197.65 lakhs, and the segment recorded an operating loss before tax.
- The quarterly profit was largely sustained by a significant tax credit, not core operations.
Why this matters
The annual turnaround headline is positive, but the underlying trend is not. A company that needs a tax credit to show a quarterly profit after a 50% sequential revenue drop is not growing its way out. The annual profit of ₹94 lakhs is thin and reliant on non-operational factors.
What we're watching
- Whether Q4's revenue drop was a one-off or the start of a new run-rate.
- The composition and repeatability of the tax credit that supported the annual result.
- Next quarter's operational performance without the tax benefit.
The full read
Brawn Biotech's FY26 results show a classic accounting turnaround: a full-year net profit of ₹94.06 lakhs against a prior-year loss of ₹179.81 lakhs. The EPS stands at ₹3.26. The problem is the trajectory. Fourth-quarter revenue collapsed over 50% sequentially to ₹197.65 lakhs, plunging the segment into an operating loss before tax. The company needed a significant tax credit to keep the quarterly number in the black. The annual profit is therefore not a story of operational recovery but a one-time adjustment. For a nano-cap, the filing is a routine periodic update; the market sees it as such.
Questions answered
- How did Brawn Biotech's full-year profit compare to last year?
- The company reported a full-year net profit of ₹94.06 lakhs for FY26, a turnaround from a net loss of ₹179.81 lakhs in FY25. This resulted in earnings per share of ₹3.26.
- Why is the fourth quarter concerning despite the annual profit?
- Q4 revenue fell over 50% sequentially to ₹197.65 lakhs, and the company recorded an operating loss before tax. The quarterly net profit was largely sustained by a significant tax credit rather than operational performance.
- What is the scale of the company's annual profit?
- At ₹94.06 lakhs, the profit is thin for a public company. The filing itself is a routine periodic update, a fixed scoring category for the market.
Story so far
All notes on BRAWN →- 29 May 2026 · 5:45 PM IST Brawn Biotech posts FY26 profit, but Q4 was weak
- 1d ago Brawn Biotech swings to ₹94 lakh profit, but the filing adds nothing new